Amgen and its subsidiary Onyx Pharmaceuticals, have reported that the Phase III FOCUS trial of Kyprolis for relapsed and refractory myeloma patients failed to meet its primary endpoint of improved overall survival. The results showed that there was no significant difference in overall survival between patients treated with Kyprolis monotherapy compared to those receiving best supportive treatment (steroid +/- cyclophosphamide). Whilst the company is unable to use this data to support regulatory submission of Kyprolis as a treatment for myeloma, it is anticipated that pending results from other trials e.g. ASPIRE, may be used instead.

Read the full article